The evaluation of the survival of patients in relation to TSLP expression (assessed in 25% of patients with higher vs. 25% with lower expression (Osuka et al. 2021)) showed poor survival rates in GBM (p < 0.01) samples from patients with higher TSLP expression compared to those with lower expression (Fig. 7A). The gene discussed is TSLP; the disease is glioblastoma.